Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice

Am J Clin Nutr. 2006 Aug;84(2):312-21. doi: 10.1093/ajcn/84.1.312.

Abstract

Background: The prevalence of dyslipidemia and obesity resulting from excess energy intake and physical inactivity is increasing. The liver plays a pivotal role in systemic lipid homeostasis. Effective, natural dietary interventions that lower plasma lipids and promote liver health are needed.

Objective: Our goal was to determine the effect of dietary sphingolipids on plasma lipids and liver steatosis.

Design: APOE*3Leiden mice were fed a Western-type diet supplemented with different sphingolipids. Body cholesterol and triacylglycerol metabolism as well as hepatic lipid concentrations and lipid-related gene expression were determined.

Results: Dietary sphingolipids dose-dependently lowered both plasma cholesterol and triacylglycerol in APOE*3Leiden mice; 1% phytosphingosine (PS) reduced plasma cholesterol and triacylglycerol by 57% and 58%, respectively. PS decreased the absorption of dietary cholesterol and free fatty acids by 50% and 40%, respectively, whereas intestinal triacylglycerol lipolysis was not affected. PS increased hepatic VLDL-triacylglycerol production by 20%, whereas plasma lipolysis was not affected. PS increased the hepatic uptake of VLDL remnants by 60%. Hepatic messenger RNA concentrations indicated enhanced hepatic lipid synthesis and VLDL and LDL uptake. The net result of these changes was a strong decrease in plasma cholesterol and triacylglycerol. The livers of 1% PS-fed mice were less pale, 22% lighter, and contained 61% less cholesteryl ester and 56% less triacylglycerol than livers of control mice. Furthermore, markers of liver inflammation (serum amyloid A) and liver damage (alanine aminotransferase) decreased by 74% and 79%, respectively, in PS-fed mice.

Conclusion: Sphingolipids lower plasma cholesterol and triacylglycerol and protect the liver from fat- and cholesterol-induced steatosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apolipoprotein E3
  • Apolipoproteins E / genetics
  • Cholesterol / blood*
  • Cholesterol, Dietary / pharmacokinetics
  • Dose-Response Relationship, Drug
  • Fatty Acids, Nonesterified / pharmacokinetics
  • Fatty Liver / prevention & control*
  • Feces / chemistry
  • Female
  • Gene Expression
  • Intestinal Absorption / drug effects
  • Lipid Metabolism / drug effects*
  • Lipid Metabolism / physiology
  • Lipolysis / drug effects
  • Lipolysis / physiology
  • Lipoproteins, VLDL / chemistry
  • Lipoproteins, VLDL / metabolism
  • Liver / drug effects
  • Liver / enzymology
  • Liver / metabolism*
  • Mice
  • Mice, Transgenic
  • RNA / metabolism
  • Random Allocation
  • Sphingolipids / administration & dosage*
  • Sphingolipids / pharmacology
  • Triglycerides / blood*

Substances

  • Apolipoprotein E3
  • Apolipoproteins E
  • Cholesterol, Dietary
  • Fatty Acids, Nonesterified
  • Lipoproteins, VLDL
  • Sphingolipids
  • Triglycerides
  • apolipoprotein E3 (Leidein)
  • RNA
  • Cholesterol